Clinical Trials Results - National Cancer Institute

Skip to content

NCI Home

Cancer Topics

Clinical Trials

Cancer Statistics

Research & Funding

News

About NCI


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -5 of 5 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 9/1/1999 First Published: 8/1/1998


1.		Phase II/III Study of Iodine I 131-Labeled Monoclonal Antibody Lym-1 in Patients with Intermediate or High Grade Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				PEREGRINE-LYM9702 TCLONE-LYM9702

Last Modified: 8/1/1990


2.		Phase I/II Pilot Study of Lym-1 Monoclonal Antibody Alone and in Combination with IL-2 in Patients with Low- or Intermediate-Grade Refractory B-Cell Lymphoma (Summary Last Modified 08/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				over 17 to physiologic 70								LAC-USC-13NHL883 NCI-B88-0010, B88-0010

Last Modified: 12/19/2002 First Published: 1/1/2001


3.		Phase I Study of Yttrium Y 90 Monoclonal Antibody Lym-1, Cyclosporine, and Paclitaxel Followed By Autologous Peripheral Blood Stem Cell Transplantation in Patients With Refractory Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				Other				UCD-991860 NCI-V00-1638, NCT00008021

Last Modified: 1/17/2003 First Published: 2/1/2001


4.		Phase I Study of Yttrium Y 90 Monoclonal Antibody Lym-1, Paclitaxel, and Cyclosporine in Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				Other				UCD-991869 NCI-V00-1641, NCT00009776

Last Modified: 6/1/1991


5.		Phase IB Study of Combination Biological Response Modifier Therapy with Murine Monoclonal Antibody Lym-1 and Human Recombinant IL-2 in Patients with Advanced B-Cell non-Hodgkin's Lymphomas (Summary Last Modified 06/91)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over								MTS-85314-NPD NCI-B89-0001, B89-0001

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute